Global Male Infertility

Male Infertility Comprehensive Study by Treatment (Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI)), Varicocele Surgery, Medication), Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Penetration Assay, Sperm Agglutination), End User (Fertility Centers, Hospitals and Clinics, Research Institutes, Other), Symptoms (Male problems, Ovulation problems, Tubal problems, Endometriosis, Cervical factors, Others) Players and Region - Global Market Outlook to 2030

Male Infertility Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Male Infertility
Infertility in men can be caused by different factors and is typically evaluated by a semen analysis. Male infertility may be treated with medical, surgical, or assisted reproductive therapies depending on the underlying cause. Medical and surgical therapies are usually managed by a urologist who specializes in infertility. A reproductive endocrinologist may offer intrauterine inseminations (IUIs) or in vitro fertilization (IVF) to help overcome male factor infertility.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


There are various companies that are exploring the market opportunities by investing in the new treatment and also expanding their footprints in new geographic regions by adopting various strategic initiatives such as mergers & acquisitions, expansions, investments, new product launches, and others. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Male Infertility market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

ASKA Pharmaceutical Co., Ltd. (Japan), Halotech DNA (Spain), Merck Serono (Germany), Cadila Healthcare (India), AbbVie (United States), Apricus Biosciences, Inc. (United States), Aytu BioScience (United States), Bristol Myers Squibb (United States), Coopersurgical, Inc. (United States) and Medical Electronic Systems (Israel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are MedITEX (Germany) and Xytex Cryo International (United States).

Segmentation Overview
AMA Research has segmented the market of Global Male Infertility market by and Region.



On the basis of geography, the market of Male Infertility has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI)) will boost the Male Infertility market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test, the sub-segment i.e. DNA Fragmentation Technique will boost the Male Infertility market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Fertility Centers will boost the Male Infertility market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Male problems will boost the Male Infertility market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Surging Development and Commercialization of Hormonal Therapy

Market Growth Drivers:
Increasing Infertility Rate, Rising Adoption of Assisted Reproductive Technologies (ART) and Growing Sedentary Lifestyle across the Globe

Challenges:
Impact of Repeated Failures in Treatments

Restraints:
High Cost of Procedures and Social Taboos

Opportunities:
Governments Initiatives to Improve the Reimbursement Scenario for Infertility-related Treatments and Increasing Healthcare Expenditure in Developing Countries

Market Leaders and their expansionary development strategies
In March 2022, Direct-to-consumer virtual care company Ro has acquired Dadi, a male fertility and sperm-testing startup. The move comes less than a year after Ro scooped up another reproductive health-focused company, Modern Fertility. As part of the deal, the virtual care company will retire the Dadi name and launch the Ro Sperm Kit, which allows users to collect samples at home for analysis and storage.
In April 2018, Sandstone Diagnostics, a medical device company focused on a data-driven approach to men’s reproductive health, proudly announces the FDA 510(k) clearance and commercial launch of the Trak Volume Cup. The patent-pending Volume Cup is the first FDA-cleared device that allows men to measure semen volume and diagnose hypospermia, or low semen volume, at home.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Male Infertility Treatment Provider, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Treatment
  • Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI))
  • Varicocele Surgery
  • Medication

By Test
  • DNA Fragmentation Technique
  • Oxidative Stress Analysis
  • Microscopic Examination
  • Sperm Penetration Assay
  • Sperm Agglutination

By End User
  • Fertility Centers
  • Hospitals and Clinics
  • Research Institutes
  • Other

By Symptoms
  • Male problems
  • Ovulation problems
  • Tubal problems
  • Endometriosis
  • Cervical factors
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Infertility Rate
      • 3.2.2. Rising Adoption of Assisted Reproductive Technologies (ART)
      • 3.2.3. Growing Sedentary Lifestyle across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Impact of Repeated Failures in Treatments
    • 3.4. Market Trends
      • 3.4.1. Surging Development and Commercialization of Hormonal Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Male Infertility, by Treatment, Test, End User, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Male Infertility (Value)
      • 5.2.1. Global Male Infertility by: Treatment (Value)
        • 5.2.1.1. Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI))
        • 5.2.1.2. Varicocele Surgery
        • 5.2.1.3. Medication
      • 5.2.2. Global Male Infertility by: Test (Value)
        • 5.2.2.1. DNA Fragmentation Technique
        • 5.2.2.2. Oxidative Stress Analysis
        • 5.2.2.3. Microscopic Examination
        • 5.2.2.4. Sperm Penetration Assay
        • 5.2.2.5. Sperm Agglutination
      • 5.2.3. Global Male Infertility by: End User (Value)
        • 5.2.3.1. Fertility Centers
        • 5.2.3.2. Hospitals and Clinics
        • 5.2.3.3. Research Institutes
        • 5.2.3.4. Other
      • 5.2.4. Global Male Infertility by: Symptoms (Value)
        • 5.2.4.1. Male problems
        • 5.2.4.2. Ovulation problems
        • 5.2.4.3. Tubal problems
        • 5.2.4.4. Endometriosis
        • 5.2.4.5. Cervical factors
        • 5.2.4.6. Others
      • 5.2.5. Global Male Infertility Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Male Infertility: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ASKA Pharmaceutical Co., Ltd. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Halotech DNA (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Serono (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cadila Healthcare (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Apricus Biosciences, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aytu BioScience (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Coopersurgical, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medical Electronic Systems (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Male Infertility Sale, by Treatment, Test, End User, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Male Infertility (Value)
      • 7.2.1. Global Male Infertility by: Treatment (Value)
        • 7.2.1.1. Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI))
        • 7.2.1.2. Varicocele Surgery
        • 7.2.1.3. Medication
      • 7.2.2. Global Male Infertility by: Test (Value)
        • 7.2.2.1. DNA Fragmentation Technique
        • 7.2.2.2. Oxidative Stress Analysis
        • 7.2.2.3. Microscopic Examination
        • 7.2.2.4. Sperm Penetration Assay
        • 7.2.2.5. Sperm Agglutination
      • 7.2.3. Global Male Infertility by: End User (Value)
        • 7.2.3.1. Fertility Centers
        • 7.2.3.2. Hospitals and Clinics
        • 7.2.3.3. Research Institutes
        • 7.2.3.4. Other
      • 7.2.4. Global Male Infertility by: Symptoms (Value)
        • 7.2.4.1. Male problems
        • 7.2.4.2. Ovulation problems
        • 7.2.4.3. Tubal problems
        • 7.2.4.4. Endometriosis
        • 7.2.4.5. Cervical factors
        • 7.2.4.6. Others
      • 7.2.5. Global Male Infertility Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Male Infertility: by Treatment(USD Million)
  • Table 2. Male Infertility Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI)) , by Region USD Million (2018-2023)
  • Table 3. Male Infertility Varicocele Surgery , by Region USD Million (2018-2023)
  • Table 4. Male Infertility Medication , by Region USD Million (2018-2023)
  • Table 5. Male Infertility: by Test(USD Million)
  • Table 6. Male Infertility DNA Fragmentation Technique , by Region USD Million (2018-2023)
  • Table 7. Male Infertility Oxidative Stress Analysis , by Region USD Million (2018-2023)
  • Table 8. Male Infertility Microscopic Examination , by Region USD Million (2018-2023)
  • Table 9. Male Infertility Sperm Penetration Assay , by Region USD Million (2018-2023)
  • Table 10. Male Infertility Sperm Agglutination , by Region USD Million (2018-2023)
  • Table 11. Male Infertility: by End User(USD Million)
  • Table 12. Male Infertility Fertility Centers , by Region USD Million (2018-2023)
  • Table 13. Male Infertility Hospitals and Clinics , by Region USD Million (2018-2023)
  • Table 14. Male Infertility Research Institutes , by Region USD Million (2018-2023)
  • Table 15. Male Infertility Other , by Region USD Million (2018-2023)
  • Table 16. Male Infertility: by Symptoms(USD Million)
  • Table 17. Male Infertility Male problems , by Region USD Million (2018-2023)
  • Table 18. Male Infertility Ovulation problems , by Region USD Million (2018-2023)
  • Table 19. Male Infertility Tubal problems , by Region USD Million (2018-2023)
  • Table 20. Male Infertility Endometriosis , by Region USD Million (2018-2023)
  • Table 21. Male Infertility Cervical factors , by Region USD Million (2018-2023)
  • Table 22. Male Infertility Others , by Region USD Million (2018-2023)
  • Table 23. South America Male Infertility, by Country USD Million (2018-2023)
  • Table 24. South America Male Infertility, by Treatment USD Million (2018-2023)
  • Table 25. South America Male Infertility, by Test USD Million (2018-2023)
  • Table 26. South America Male Infertility, by End User USD Million (2018-2023)
  • Table 27. South America Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 28. Brazil Male Infertility, by Treatment USD Million (2018-2023)
  • Table 29. Brazil Male Infertility, by Test USD Million (2018-2023)
  • Table 30. Brazil Male Infertility, by End User USD Million (2018-2023)
  • Table 31. Brazil Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 32. Argentina Male Infertility, by Treatment USD Million (2018-2023)
  • Table 33. Argentina Male Infertility, by Test USD Million (2018-2023)
  • Table 34. Argentina Male Infertility, by End User USD Million (2018-2023)
  • Table 35. Argentina Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 36. Rest of South America Male Infertility, by Treatment USD Million (2018-2023)
  • Table 37. Rest of South America Male Infertility, by Test USD Million (2018-2023)
  • Table 38. Rest of South America Male Infertility, by End User USD Million (2018-2023)
  • Table 39. Rest of South America Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 40. Asia Pacific Male Infertility, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Male Infertility, by Treatment USD Million (2018-2023)
  • Table 42. Asia Pacific Male Infertility, by Test USD Million (2018-2023)
  • Table 43. Asia Pacific Male Infertility, by End User USD Million (2018-2023)
  • Table 44. Asia Pacific Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 45. China Male Infertility, by Treatment USD Million (2018-2023)
  • Table 46. China Male Infertility, by Test USD Million (2018-2023)
  • Table 47. China Male Infertility, by End User USD Million (2018-2023)
  • Table 48. China Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 49. Japan Male Infertility, by Treatment USD Million (2018-2023)
  • Table 50. Japan Male Infertility, by Test USD Million (2018-2023)
  • Table 51. Japan Male Infertility, by End User USD Million (2018-2023)
  • Table 52. Japan Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 53. India Male Infertility, by Treatment USD Million (2018-2023)
  • Table 54. India Male Infertility, by Test USD Million (2018-2023)
  • Table 55. India Male Infertility, by End User USD Million (2018-2023)
  • Table 56. India Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 57. South Korea Male Infertility, by Treatment USD Million (2018-2023)
  • Table 58. South Korea Male Infertility, by Test USD Million (2018-2023)
  • Table 59. South Korea Male Infertility, by End User USD Million (2018-2023)
  • Table 60. South Korea Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 61. Taiwan Male Infertility, by Treatment USD Million (2018-2023)
  • Table 62. Taiwan Male Infertility, by Test USD Million (2018-2023)
  • Table 63. Taiwan Male Infertility, by End User USD Million (2018-2023)
  • Table 64. Taiwan Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 65. Australia Male Infertility, by Treatment USD Million (2018-2023)
  • Table 66. Australia Male Infertility, by Test USD Million (2018-2023)
  • Table 67. Australia Male Infertility, by End User USD Million (2018-2023)
  • Table 68. Australia Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Male Infertility, by Treatment USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Male Infertility, by Test USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Male Infertility, by End User USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 73. Europe Male Infertility, by Country USD Million (2018-2023)
  • Table 74. Europe Male Infertility, by Treatment USD Million (2018-2023)
  • Table 75. Europe Male Infertility, by Test USD Million (2018-2023)
  • Table 76. Europe Male Infertility, by End User USD Million (2018-2023)
  • Table 77. Europe Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 78. Germany Male Infertility, by Treatment USD Million (2018-2023)
  • Table 79. Germany Male Infertility, by Test USD Million (2018-2023)
  • Table 80. Germany Male Infertility, by End User USD Million (2018-2023)
  • Table 81. Germany Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 82. France Male Infertility, by Treatment USD Million (2018-2023)
  • Table 83. France Male Infertility, by Test USD Million (2018-2023)
  • Table 84. France Male Infertility, by End User USD Million (2018-2023)
  • Table 85. France Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 86. Italy Male Infertility, by Treatment USD Million (2018-2023)
  • Table 87. Italy Male Infertility, by Test USD Million (2018-2023)
  • Table 88. Italy Male Infertility, by End User USD Million (2018-2023)
  • Table 89. Italy Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 90. United Kingdom Male Infertility, by Treatment USD Million (2018-2023)
  • Table 91. United Kingdom Male Infertility, by Test USD Million (2018-2023)
  • Table 92. United Kingdom Male Infertility, by End User USD Million (2018-2023)
  • Table 93. United Kingdom Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 94. Netherlands Male Infertility, by Treatment USD Million (2018-2023)
  • Table 95. Netherlands Male Infertility, by Test USD Million (2018-2023)
  • Table 96. Netherlands Male Infertility, by End User USD Million (2018-2023)
  • Table 97. Netherlands Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 98. Rest of Europe Male Infertility, by Treatment USD Million (2018-2023)
  • Table 99. Rest of Europe Male Infertility, by Test USD Million (2018-2023)
  • Table 100. Rest of Europe Male Infertility, by End User USD Million (2018-2023)
  • Table 101. Rest of Europe Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 102. MEA Male Infertility, by Country USD Million (2018-2023)
  • Table 103. MEA Male Infertility, by Treatment USD Million (2018-2023)
  • Table 104. MEA Male Infertility, by Test USD Million (2018-2023)
  • Table 105. MEA Male Infertility, by End User USD Million (2018-2023)
  • Table 106. MEA Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 107. Middle East Male Infertility, by Treatment USD Million (2018-2023)
  • Table 108. Middle East Male Infertility, by Test USD Million (2018-2023)
  • Table 109. Middle East Male Infertility, by End User USD Million (2018-2023)
  • Table 110. Middle East Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 111. Africa Male Infertility, by Treatment USD Million (2018-2023)
  • Table 112. Africa Male Infertility, by Test USD Million (2018-2023)
  • Table 113. Africa Male Infertility, by End User USD Million (2018-2023)
  • Table 114. Africa Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 115. North America Male Infertility, by Country USD Million (2018-2023)
  • Table 116. North America Male Infertility, by Treatment USD Million (2018-2023)
  • Table 117. North America Male Infertility, by Test USD Million (2018-2023)
  • Table 118. North America Male Infertility, by End User USD Million (2018-2023)
  • Table 119. North America Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 120. United States Male Infertility, by Treatment USD Million (2018-2023)
  • Table 121. United States Male Infertility, by Test USD Million (2018-2023)
  • Table 122. United States Male Infertility, by End User USD Million (2018-2023)
  • Table 123. United States Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 124. Canada Male Infertility, by Treatment USD Million (2018-2023)
  • Table 125. Canada Male Infertility, by Test USD Million (2018-2023)
  • Table 126. Canada Male Infertility, by End User USD Million (2018-2023)
  • Table 127. Canada Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 128. Mexico Male Infertility, by Treatment USD Million (2018-2023)
  • Table 129. Mexico Male Infertility, by Test USD Million (2018-2023)
  • Table 130. Mexico Male Infertility, by End User USD Million (2018-2023)
  • Table 131. Mexico Male Infertility, by Symptoms USD Million (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Male Infertility: by Treatment(USD Million)
  • Table 143. Male Infertility Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI)) , by Region USD Million (2025-2030)
  • Table 144. Male Infertility Varicocele Surgery , by Region USD Million (2025-2030)
  • Table 145. Male Infertility Medication , by Region USD Million (2025-2030)
  • Table 146. Male Infertility: by Test(USD Million)
  • Table 147. Male Infertility DNA Fragmentation Technique , by Region USD Million (2025-2030)
  • Table 148. Male Infertility Oxidative Stress Analysis , by Region USD Million (2025-2030)
  • Table 149. Male Infertility Microscopic Examination , by Region USD Million (2025-2030)
  • Table 150. Male Infertility Sperm Penetration Assay , by Region USD Million (2025-2030)
  • Table 151. Male Infertility Sperm Agglutination , by Region USD Million (2025-2030)
  • Table 152. Male Infertility: by End User(USD Million)
  • Table 153. Male Infertility Fertility Centers , by Region USD Million (2025-2030)
  • Table 154. Male Infertility Hospitals and Clinics , by Region USD Million (2025-2030)
  • Table 155. Male Infertility Research Institutes , by Region USD Million (2025-2030)
  • Table 156. Male Infertility Other , by Region USD Million (2025-2030)
  • Table 157. Male Infertility: by Symptoms(USD Million)
  • Table 158. Male Infertility Male problems , by Region USD Million (2025-2030)
  • Table 159. Male Infertility Ovulation problems , by Region USD Million (2025-2030)
  • Table 160. Male Infertility Tubal problems , by Region USD Million (2025-2030)
  • Table 161. Male Infertility Endometriosis , by Region USD Million (2025-2030)
  • Table 162. Male Infertility Cervical factors , by Region USD Million (2025-2030)
  • Table 163. Male Infertility Others , by Region USD Million (2025-2030)
  • Table 164. South America Male Infertility, by Country USD Million (2025-2030)
  • Table 165. South America Male Infertility, by Treatment USD Million (2025-2030)
  • Table 166. South America Male Infertility, by Test USD Million (2025-2030)
  • Table 167. South America Male Infertility, by End User USD Million (2025-2030)
  • Table 168. South America Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 169. Brazil Male Infertility, by Treatment USD Million (2025-2030)
  • Table 170. Brazil Male Infertility, by Test USD Million (2025-2030)
  • Table 171. Brazil Male Infertility, by End User USD Million (2025-2030)
  • Table 172. Brazil Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 173. Argentina Male Infertility, by Treatment USD Million (2025-2030)
  • Table 174. Argentina Male Infertility, by Test USD Million (2025-2030)
  • Table 175. Argentina Male Infertility, by End User USD Million (2025-2030)
  • Table 176. Argentina Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 177. Rest of South America Male Infertility, by Treatment USD Million (2025-2030)
  • Table 178. Rest of South America Male Infertility, by Test USD Million (2025-2030)
  • Table 179. Rest of South America Male Infertility, by End User USD Million (2025-2030)
  • Table 180. Rest of South America Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 181. Asia Pacific Male Infertility, by Country USD Million (2025-2030)
  • Table 182. Asia Pacific Male Infertility, by Treatment USD Million (2025-2030)
  • Table 183. Asia Pacific Male Infertility, by Test USD Million (2025-2030)
  • Table 184. Asia Pacific Male Infertility, by End User USD Million (2025-2030)
  • Table 185. Asia Pacific Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 186. China Male Infertility, by Treatment USD Million (2025-2030)
  • Table 187. China Male Infertility, by Test USD Million (2025-2030)
  • Table 188. China Male Infertility, by End User USD Million (2025-2030)
  • Table 189. China Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 190. Japan Male Infertility, by Treatment USD Million (2025-2030)
  • Table 191. Japan Male Infertility, by Test USD Million (2025-2030)
  • Table 192. Japan Male Infertility, by End User USD Million (2025-2030)
  • Table 193. Japan Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 194. India Male Infertility, by Treatment USD Million (2025-2030)
  • Table 195. India Male Infertility, by Test USD Million (2025-2030)
  • Table 196. India Male Infertility, by End User USD Million (2025-2030)
  • Table 197. India Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 198. South Korea Male Infertility, by Treatment USD Million (2025-2030)
  • Table 199. South Korea Male Infertility, by Test USD Million (2025-2030)
  • Table 200. South Korea Male Infertility, by End User USD Million (2025-2030)
  • Table 201. South Korea Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 202. Taiwan Male Infertility, by Treatment USD Million (2025-2030)
  • Table 203. Taiwan Male Infertility, by Test USD Million (2025-2030)
  • Table 204. Taiwan Male Infertility, by End User USD Million (2025-2030)
  • Table 205. Taiwan Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 206. Australia Male Infertility, by Treatment USD Million (2025-2030)
  • Table 207. Australia Male Infertility, by Test USD Million (2025-2030)
  • Table 208. Australia Male Infertility, by End User USD Million (2025-2030)
  • Table 209. Australia Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Male Infertility, by Treatment USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Male Infertility, by Test USD Million (2025-2030)
  • Table 212. Rest of Asia-Pacific Male Infertility, by End User USD Million (2025-2030)
  • Table 213. Rest of Asia-Pacific Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 214. Europe Male Infertility, by Country USD Million (2025-2030)
  • Table 215. Europe Male Infertility, by Treatment USD Million (2025-2030)
  • Table 216. Europe Male Infertility, by Test USD Million (2025-2030)
  • Table 217. Europe Male Infertility, by End User USD Million (2025-2030)
  • Table 218. Europe Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 219. Germany Male Infertility, by Treatment USD Million (2025-2030)
  • Table 220. Germany Male Infertility, by Test USD Million (2025-2030)
  • Table 221. Germany Male Infertility, by End User USD Million (2025-2030)
  • Table 222. Germany Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 223. France Male Infertility, by Treatment USD Million (2025-2030)
  • Table 224. France Male Infertility, by Test USD Million (2025-2030)
  • Table 225. France Male Infertility, by End User USD Million (2025-2030)
  • Table 226. France Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 227. Italy Male Infertility, by Treatment USD Million (2025-2030)
  • Table 228. Italy Male Infertility, by Test USD Million (2025-2030)
  • Table 229. Italy Male Infertility, by End User USD Million (2025-2030)
  • Table 230. Italy Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 231. United Kingdom Male Infertility, by Treatment USD Million (2025-2030)
  • Table 232. United Kingdom Male Infertility, by Test USD Million (2025-2030)
  • Table 233. United Kingdom Male Infertility, by End User USD Million (2025-2030)
  • Table 234. United Kingdom Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 235. Netherlands Male Infertility, by Treatment USD Million (2025-2030)
  • Table 236. Netherlands Male Infertility, by Test USD Million (2025-2030)
  • Table 237. Netherlands Male Infertility, by End User USD Million (2025-2030)
  • Table 238. Netherlands Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 239. Rest of Europe Male Infertility, by Treatment USD Million (2025-2030)
  • Table 240. Rest of Europe Male Infertility, by Test USD Million (2025-2030)
  • Table 241. Rest of Europe Male Infertility, by End User USD Million (2025-2030)
  • Table 242. Rest of Europe Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 243. MEA Male Infertility, by Country USD Million (2025-2030)
  • Table 244. MEA Male Infertility, by Treatment USD Million (2025-2030)
  • Table 245. MEA Male Infertility, by Test USD Million (2025-2030)
  • Table 246. MEA Male Infertility, by End User USD Million (2025-2030)
  • Table 247. MEA Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 248. Middle East Male Infertility, by Treatment USD Million (2025-2030)
  • Table 249. Middle East Male Infertility, by Test USD Million (2025-2030)
  • Table 250. Middle East Male Infertility, by End User USD Million (2025-2030)
  • Table 251. Middle East Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 252. Africa Male Infertility, by Treatment USD Million (2025-2030)
  • Table 253. Africa Male Infertility, by Test USD Million (2025-2030)
  • Table 254. Africa Male Infertility, by End User USD Million (2025-2030)
  • Table 255. Africa Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 256. North America Male Infertility, by Country USD Million (2025-2030)
  • Table 257. North America Male Infertility, by Treatment USD Million (2025-2030)
  • Table 258. North America Male Infertility, by Test USD Million (2025-2030)
  • Table 259. North America Male Infertility, by End User USD Million (2025-2030)
  • Table 260. North America Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 261. United States Male Infertility, by Treatment USD Million (2025-2030)
  • Table 262. United States Male Infertility, by Test USD Million (2025-2030)
  • Table 263. United States Male Infertility, by End User USD Million (2025-2030)
  • Table 264. United States Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 265. Canada Male Infertility, by Treatment USD Million (2025-2030)
  • Table 266. Canada Male Infertility, by Test USD Million (2025-2030)
  • Table 267. Canada Male Infertility, by End User USD Million (2025-2030)
  • Table 268. Canada Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 269. Mexico Male Infertility, by Treatment USD Million (2025-2030)
  • Table 270. Mexico Male Infertility, by Test USD Million (2025-2030)
  • Table 271. Mexico Male Infertility, by End User USD Million (2025-2030)
  • Table 272. Mexico Male Infertility, by Symptoms USD Million (2025-2030)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Male Infertility: by Treatment USD Million (2018-2023)
  • Figure 5. Global Male Infertility: by Test USD Million (2018-2023)
  • Figure 6. Global Male Infertility: by End User USD Million (2018-2023)
  • Figure 7. Global Male Infertility: by Symptoms USD Million (2018-2023)
  • Figure 8. South America Male Infertility Share (%), by Country
  • Figure 9. Asia Pacific Male Infertility Share (%), by Country
  • Figure 10. Europe Male Infertility Share (%), by Country
  • Figure 11. MEA Male Infertility Share (%), by Country
  • Figure 12. North America Male Infertility Share (%), by Country
  • Figure 13. Global Male Infertility share by Players 2023 (%)
  • Figure 14. Global Male Infertility share by Players (Top 3) 2023(%)
  • Figure 15. Global Male Infertility share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ASKA Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 18. ASKA Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 19. Halotech DNA (Spain) Revenue, Net Income and Gross profit
  • Figure 20. Halotech DNA (Spain) Revenue: by Geography 2023
  • Figure 21. Merck Serono (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Merck Serono (Germany) Revenue: by Geography 2023
  • Figure 23. Cadila Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 24. Cadila Healthcare (India) Revenue: by Geography 2023
  • Figure 25. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 26. AbbVie (United States) Revenue: by Geography 2023
  • Figure 27. Apricus Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Apricus Biosciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Aytu BioScience (United States) Revenue, Net Income and Gross profit
  • Figure 30. Aytu BioScience (United States) Revenue: by Geography 2023
  • Figure 31. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 33. Coopersurgical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Coopersurgical, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Medical Electronic Systems (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Medical Electronic Systems (Israel) Revenue: by Geography 2023
  • Figure 37. Global Male Infertility: by Treatment USD Million (2025-2030)
  • Figure 38. Global Male Infertility: by Test USD Million (2025-2030)
  • Figure 39. Global Male Infertility: by End User USD Million (2025-2030)
  • Figure 40. Global Male Infertility: by Symptoms USD Million (2025-2030)
  • Figure 41. South America Male Infertility Share (%), by Country
  • Figure 42. Asia Pacific Male Infertility Share (%), by Country
  • Figure 43. Europe Male Infertility Share (%), by Country
  • Figure 44. MEA Male Infertility Share (%), by Country
  • Figure 45. North America Male Infertility Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ASKA Pharmaceutical Co., Ltd. (Japan)
  • Halotech DNA (Spain)
  • Merck Serono (Germany)
  • Cadila Healthcare (India)
  • AbbVie (United States)
  • Apricus Biosciences, Inc. (United States)
  • Aytu BioScience (United States)
  • Bristol Myers Squibb (United States)
  • Coopersurgical, Inc. (United States)
  • Medical Electronic Systems (Israel)
Additional players considered in the study are as follows:
MedITEX (Germany) , Xytex Cryo International (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 211 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Male Infertility Quantitative research analysis
Global Male Infertility Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as ASKA Pharmaceutical Co., Ltd. (Japan), Halotech DNA (Spain), Merck Serono (Germany), Cadila Healthcare (India), AbbVie (United States), Apricus Biosciences, Inc. (United States), Aytu BioScience (United States), Bristol Myers Squibb (United States), Coopersurgical, Inc. (United States) and Medical Electronic Systems (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Surging Development and Commercialization of Hormonal Therapy" is seen as one of major influencing trends for Male Infertility Market during projected period 2023-2030.
The Male Infertility market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Male Infertility Report?

Have a Query? Click Here

Other Related Reports

Postmenopausal Vaginal Atrophy Treatment Comprehensive Study by Type (Prasterone (Intrarosa)), Application (Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina...
$ 3650
Meningitis Diagnostic Testing Comprehensive Study by Application (Viral Meningitis, Bacterial Meningitis, Fungal Meningitis, Hib Meningitis, Others), Test Type (Latex Agglutination Tests, Lateral Flo...
$ 3650
Hemostasis Diagnostics Comprehensive Study by Type (Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems), Point-of-Care Testing Systems), Application (Hospital/Clinics, In...
$ 3750
Genetic Modification Therapies Comprehensive Study by Type (Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies, Gene Editing), Application (Hospitals, Diagnostics and Testing Laborato...
$ 3450
Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Th...
$ 3650
Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluoresce...
$ 3650